Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Net Cash Flow (2016 - 2025)

Cardiff Oncology's Net Cash Flow history spans 15 years, with the latest figure at $7.3 million for Q4 2025.

  • For Q4 2025, Net Cash Flow fell 80.91% year-over-year to $7.3 million; the TTM value through Dec 2025 reached -$34.0 million, down 214.04%, while the annual FY2025 figure was -$34.0 million, 214.04% down from the prior year.
  • Net Cash Flow for Q4 2025 was $7.3 million at Cardiff Oncology, up from -$649000.0 in the prior quarter.
  • Across five years, Net Cash Flow topped out at $38.4 million in Q4 2024 and bottomed at -$116.3 million in Q1 2021.
  • The 5-year median for Net Cash Flow is -$1.3 million (2021), against an average of -$5.7 million.
  • The largest annual shift saw Net Cash Flow tumbled 12570.92% in 2021 before it skyrocketed 498.44% in 2024.
  • A 5-year view of Net Cash Flow shows it stood at -$1.2 million in 2021, then tumbled by 93.94% to -$2.4 million in 2022, then surged by 370.97% to $6.4 million in 2023, then surged by 498.44% to $38.4 million in 2024, then crashed by 80.91% to $7.3 million in 2025.
  • Per Business Quant, the three most recent readings for CRDF's Net Cash Flow are $7.3 million (Q4 2025), -$649000.0 (Q3 2025), and -$13.3 million (Q2 2025).